
Bydureon has been outperformed by rival Victoza in a head-to-trial, decimating shares in its co-developer Amylin and Alkermes, the company …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

